UCL News


Breast cancer sufferers could be better off taking vital drug for just nine weeks

3 March 2017

Dr Caroline Clarke (UCL Primary Care & Population Health) led a study finding that breast cancer patients who receive the drug Herceptin for nine weeks as part of their post-surgery chemotherapy regime may enjoy better health outcomes compared to those who receive it for the NHS-recommended 12 months. Read: Mirror, More: UCL News